Sang‐Kyung Jo

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury

Gang-Jee Ko, Chang Su Boo, Sang‐Kyung Jo et al. · Nephrology Dialysis Transplantation · 2007 · 210 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Early detection of cysteine rich protein 61 (CYR61, CCN1) in urine following renal ischemic reperfusion injury

Yasunari Muramatsu, Michiko Tsujie, Yukimasa Kohda et al. · Kidney International · 2002 · 153 citations · Full text

Urology, Renal Function, Biochemistry +9

Role of vascular endothelial growth factor in diabetic nephropathy

Dae Ryong, Nan Hee Kim, Jong‐Woo Yoon et al. · Kidney International · 2000 · 140 citations · Full text

Medicine, Microvascular Dysfunction, Physiology +8